France is one of Europe’s most important clinical trial markets.
With a population of 68 million and more than 34,000 studies featuring French sites, France offers sponsors scale, scientific depth and access to a nationally distributed research infrastructure.
Its biggest strength is oncology. France combines Gustave Roussy, Institut Curie, the Unicancer network of 18 cancer centers, AP HP’s university hospital system and strong early phase oncology capabilities.
The country is also highly relevant for rare disease, neuroscience, advanced therapies, infectious disease, cardiovascular research, pediatrics, immunology and metabolic research.
For sponsors, France is not just a large Western European market. It is a credibility market where academic strength, investigator quality, oncology leadership and regulatory modernization all matter.